Biliary stone disease in patients receiving somatostatin analogs for neuroendocrine neoplasms. A retrospective observational study

Background Somatostatin analogs are the backbone of neuroendocrine neoplasms treatment. Biliary stone disease is a potentially severe adverse event of somatostatin analogs: an increased incidence has been reported in somatostatin analogs-treated acromegalic patients, but studies on patients with neuroendocrine neoplasms are lacking. Aims To evaluate biliary stone disease incidence and associated factors in a large series of patients treated with...